Japanese maker of patient monitors, ECG machines and other diagnostic medical devices for hospitals and clinics.
Japanese maker of patient monitors, ECG machines and other diagnostic medical devices for hospitals and clinics.
Sells monitors and ECG machines through its own domestic sales and service network to hospitals, then earns follow-on income from maintenance and the electrodes, paper and sensors those machines use. Most sales are in Japan.
In one line: A smaller Japanese GE Healthcare (patient monitoring).
Moat: narrow (installed base, regulatory licence). Long-standing hospital equipment relationships and regulatory approvals support recurring replacement sales.
Headquarters: Kawasaki, Japan · Founded: 1939 · Employees: 3,497
Size Fukuda Denshi (6960.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.84B, the 514th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥10,250 on 18 Nov 2026.
Performance Over six months the shares gained 3.5%, against +1.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 0.1% over the last twelve months (peer median +14.5%); the operating margin is 19.0% (peer median 13.6%).
Valuation It trades at 15.4× forward earnings against a peer median of 25.1× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.4 points above its cost of capital (7.5% WACC).
Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥140B | ¥140B | ¥139B | ¥140B | ¥135B |
| Revenue growth | — | 0% | -1% | +4% | — |
| Gross profit | ¥76.2B | ¥74.6B | ¥72.1B | ¥72.7B | ¥68.6B |
| EBITDA | ¥39.0B | ¥38.5B | ¥36.4B | ¥36.2B | ¥33.5B |
| Net income | ¥18.5B | ¥18.8B | ¥18.6B | ¥18.7B | ¥17.3B |
| Free cash flow | n/a | ¥10.1B | ¥20.5B | ¥10.4B | ¥11.2B |
| Capital expenditure | n/a | ¥19.9B | ¥12.9B | ¥14.1B | ¥12.5B |
| Total debt | ¥4.45B | ¥3.48B | ¥3.32B | ¥3.51B | ¥3.68B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Fukuda Denshi 6960.T | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% |
| Nihon Kohden 6849.T | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% |
| Draegerwerk AG & Co. KGaA DRW8.DE | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% |
| Baxter International BAX | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6960.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | -4.4% | 9th lowest of 21 |
| 6-month return | +3.5% | +1.5% | 10th highest of 20 |
| Distance from 52-week high | -17.9% | -24.8% | 8th highest of 21 |
| Revenue growth (TTM) | +0.1% | +14.5% | 3rd lowest of 21 |
| Operating margin | 19.0% | 13.6% | 6th highest of 21 |
| Forward P/E | 15.4× | 25.1× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 13.2% | 3rd least demanding of 15 |
| Growth delivered (Del g) | -1.0% | +13.5% | lowest of 15 |
| Hurdle (Req g minus delivered) | -0.6 pp | -9.6 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | +6.4 pp | +0.6 pp | 6th highest of 21 |
| EV / EBITDA | 5.9× | 17.9× | 2nd cheapest of 16 |
| Net debt / EBITDA | -1.6× | -0.8× | 5th least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |